Peeraporn VarinthraShun Ping HuangSupin ChompoopongZhi Hong WenIngrid Y. LiuSiriraj HospitalTzu Chi UniversityNational Sun Yat-Sen University2022-08-042022-08-042021-01-01Marine Drugs. Vol.19, No.1 (2021)166033972-s2.0-85099114917https://repository.li.mahidol.ac.th/handle/123456789/78985Age-related macular degeneration (AMD) is a progressive eye disease that causes irreversible impairment of central vision, and effective treatment is not yet available. Extracellular accumulation of amyloid-beta (Aβ) in drusen that lie under the retinal pigment epithelium (RPE) has been reported as one of the early signs of AMD and was found in more than 60% of Alzheimer’s disease (AD) patients. Extracellular deposition of Aβ can induce the expression of inflammatory cytokines such as IL-1β, TNF-α, COX-2, and iNOS in RPE cells. Thus, finding a compound that can effectively reduce the inflammatory response may help the treatment of AMD. In this research, we investigated the anti-inflammatory effect of the coral-derived compound 4-(phenylsulfanyl) butan-2-one (4-PSB-2) on Aβ1-42 oligomer (oAβ1-42 ) added to the human adult retinal pigment epithelial cell line (ARPE-19). Our results demonstrated that 4-PSB-2 can decrease the elevated expressions of TNF-α, COX-2, and iNOS via NF-κB signaling in ARPE-19 cells treated with oAβ1-42 without causing any cytotoxicity or notable side effects. This study suggests that 4-PSB-2 is a promising drug candidate for attenuation of AMD.Mahidol UniversityPharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.3390/md19010001